Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Sort descending Date Recommendation Issued
N/A bevacizumab and lomustine Recurrent glioblastoma multiform Reimburse with clinical criteria and/or conditions Complete
Polivy polatuzumab vedotin Large B-cell lymphoma Do not reimburse Complete
Ondexxya andexanet alfa Reversal of FXa inhibitor anticoagulant effects Do not reimburse Complete
N/A eltrombopag Severe Aplastic Anemia (SAA) Reimburse with clinical criteria and/or conditions Active
Atriance nelarabine T-cell acute lymphoblastic leukemia Reimburse with clinical criteria and/or conditions Complete
Omvoh mirikizumab Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete
Imcivree setmelanotide Bardet-Biedl syndrome Reimburse with clinical criteria and/or conditions Complete
Dupixent dupilumab Atopic dermatitis, pediatrics Reimburse with clinical criteria and/or conditions Complete
Yescarta axicabtagene ciloleucel Relapsed or refractory follicular lymphoma Reimburse with clinical criteria and/or conditions Complete
Imbruvica ibrutinib Chronic lymphocytic leukemia (CLL) Reimburse with clinical criteria and/or conditions Complete